MX344257B - Agentes antimicrobianos. - Google Patents
Agentes antimicrobianos.Info
- Publication number
- MX344257B MX344257B MX2013007313A MX2013007313A MX344257B MX 344257 B MX344257 B MX 344257B MX 2013007313 A MX2013007313 A MX 2013007313A MX 2013007313 A MX2013007313 A MX 2013007313A MX 344257 B MX344257 B MX 344257B
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- gram
- relates
- present
- synthetic
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 abstract 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000000541 Defensins Human genes 0.000 abstract 1
- 108010002069 Defensins Proteins 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 239000000645 desinfectant Substances 0.000 abstract 1
- -1 diagnostic means Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a una proteína de fusión compuesta de una enzima que tiene la actividad de degradar la pared celular de las bacterias Gram-negativas y/o bacterias Gram-positivas y al menos dos alargamientos de péptidos fusionados a la enzima en el N-o C-Terminal, caracterizada porque los alargamientos de péptido tienen una longitud de 5 a 50 residuos de aminoácidos y en donde los alargamientos de péptido son un péptido policatiónico y un péptido antimicrobiano; y en donde la enzima exhibe una secuencia de aminoácido que se selecciona del grupo que consiste de las SEC ID NOS: 1ª 18, en donde al menos 70% de los residuos de aminoácido del péptido policatiónico son residuos de aminoácido positivamente cargados, en particular de lisina y/o arginina, y en donde el péptido antimicrobiano exhibe una secuencia de aminoácido que se selecciona del grupo que consiste de la SEC ID Nos: 44 a 63 y 78 a 98.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196890A EP2468856A1 (en) | 2010-12-23 | 2010-12-23 | Antimicrobial Agents |
| PCT/EP2011/073908 WO2012085259A2 (en) | 2010-12-23 | 2011-12-23 | Antimicrobial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013007313A MX2013007313A (es) | 2013-10-25 |
| MX344257B true MX344257B (es) | 2016-12-09 |
Family
ID=44310766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007313A MX344257B (es) | 2010-12-23 | 2011-12-23 | Agentes antimicrobianos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130344055A1 (es) |
| EP (2) | EP2468856A1 (es) |
| JP (1) | JP2014507933A (es) |
| CN (1) | CN103403153A (es) |
| AR (1) | AR084536A1 (es) |
| AU (1) | AU2011347152B2 (es) |
| CA (1) | CA2822732C (es) |
| EA (1) | EA201370145A1 (es) |
| MX (1) | MX344257B (es) |
| TW (1) | TW201239095A (es) |
| WO (1) | WO2012085259A2 (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2679677A1 (en) * | 2012-06-29 | 2014-01-01 | Lysando Aktiengesellschaft | Composition for use in Mycobacteria therapy |
| WO2014001571A1 (en) * | 2012-06-29 | 2014-01-03 | Lysando Ag | Composition for use in mycobacteria diagnosis |
| WO2015070912A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| WO2015070911A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified kz144 endolysin sequence |
| WO2015121443A1 (en) * | 2014-02-14 | 2015-08-20 | Lysando Ag | Antimicrobial agents |
| CA2941426C (en) * | 2014-04-08 | 2022-09-27 | Lysando Ag | Pharmaceutical composition against chronic bacterial infections |
| AU2015279705B2 (en) * | 2014-06-26 | 2021-04-01 | The Rockefeller University | Acinetobacter lysins |
| WO2016130024A1 (en) * | 2015-02-13 | 2016-08-18 | Supreme Biotechnologies Limited | Endolysin expression platform |
| US10017542B2 (en) * | 2015-03-23 | 2018-07-10 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of use thereof |
| AU2016324307B2 (en) | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| EP3464583A1 (en) | 2016-05-27 | 2019-04-10 | Sasinapas Co., Ltd. | Endolysin variant |
| US11427812B2 (en) * | 2016-11-18 | 2022-08-30 | Lysando Ag | Antimicrobial agents against Staphylococcus aureus |
| AU2018248060B2 (en) * | 2017-04-03 | 2024-05-23 | Sasinapas Co., Ltd. | Engineered Gram-negative endolysins |
| CN110256570B (zh) * | 2017-12-26 | 2021-01-05 | 杭州皇冠农业生物工程技术研究中心有限公司 | 一种重组融合抗菌肽及应用 |
| CN108251330B (zh) * | 2017-12-28 | 2021-03-23 | 江苏世邦生物工程科技有限公司 | 用于治理土壤污染的复合微生物菌剂及其制备方法和应用 |
| US10738093B2 (en) * | 2018-01-25 | 2020-08-11 | The Hong Kong University Of Science And Technology | Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining |
| CN112368376A (zh) | 2018-03-29 | 2021-02-12 | 康特拉费克特公司 | 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途 |
| CN108410840A (zh) * | 2018-04-03 | 2018-08-17 | 大连理工大学 | 一种铜绿假单胞菌噬菌体内溶素及其编码基因与应用 |
| US20210169985A1 (en) * | 2018-05-04 | 2021-06-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating gram positive bacterial infection |
| US11958890B2 (en) | 2018-05-30 | 2024-04-16 | Lysando Ag | Antimicrobial proteins |
| EP3802620A1 (en) * | 2018-05-30 | 2021-04-14 | Lysando AG | Novel antimicrobial fusion proteins |
| JP7492503B2 (ja) * | 2018-08-28 | 2024-05-29 | ウルツファルマ・アクチェボラグ | ペプチド化合物 |
| GB201901364D0 (en) * | 2019-01-31 | 2019-03-20 | Axitan Ltd | Endolysins |
| CN120136980A (zh) * | 2019-05-08 | 2025-06-13 | 生物技术公司 | 新的加德纳菌内溶素及其用途 |
| WO2021042039A1 (en) * | 2019-08-29 | 2021-03-04 | Ajk Pharmaceutical Llc | Synthetic antimicrobial peptides |
| MX2022011291A (es) * | 2020-03-11 | 2022-12-08 | Telum Therapeutics S L | Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. |
| CA3171721A1 (en) | 2020-03-19 | 2021-09-23 | Fritz Eichenseher | A stabilized protein of interest |
| IT202000006481A1 (it) * | 2020-03-27 | 2021-09-27 | Sanidrink S R L | Condotti tubolari antimicrobici |
| IT202000006511A1 (it) * | 2020-03-27 | 2021-09-27 | Materias S R L | Peptidi antimicrobici |
| WO2021235876A1 (ko) * | 2020-05-22 | 2021-11-25 | 주식회사 라이센텍 | 신규한 폴리펩타이드, 융합 폴리펩타이드, 및 이를 포함하는 그람음성균에 대한 항생제 |
| CN111955538B (zh) * | 2020-08-10 | 2022-09-30 | 浙江工商大学 | 一种大黄鱼保鲜剂及其使用方法 |
| CN112480230B (zh) * | 2020-11-30 | 2022-05-03 | 青岛农业大学 | 一种具有更好抗热功能的抗菌肽及其应用 |
| CN115029410A (zh) * | 2021-03-04 | 2022-09-09 | 中国科学院微生物研究所 | 屎肠球菌作为预测呼吸重症患者临床结局及预后标志物中的应用 |
| CN115323023B (zh) * | 2021-12-17 | 2024-05-03 | 河南牧业经济学院 | 一种治疗奶牛乳房炎药物的制备方法 |
| CN114651819A (zh) * | 2022-03-10 | 2022-06-24 | 上海芜玮建晖生物科技有限公司 | 一种基于海洋资源的有机消毒剂 |
| CN115433686B (zh) * | 2022-06-14 | 2024-03-22 | 天津市农业科学院 | 死亡素和斑点叉尾鮰β-防御素基因重组毕赤酵母的构建方法及应用 |
| CN115873076B (zh) * | 2022-11-24 | 2024-07-16 | 青岛农业大学 | 一种抗菌肽及其在枯草芽孢杆菌中的表达和应用 |
| WO2024241070A1 (en) | 2023-05-22 | 2024-11-28 | L'oreal | Cosmetic composition comprising an endolysin and a polyvinyl alcohol |
| FR3149209B1 (fr) | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| FR3149207B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique comprenant une endolysine et un composé de formule (I) |
| FR3152395A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone |
| FR3149202B1 (fr) | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| FR3149206B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique aqueuse comprenant une endolysine et du tréhalose |
| FR3149204B1 (fr) | 2023-06-02 | 2026-02-13 | Oreal | Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate |
| EP4719330A1 (en) | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149205B1 (fr) | 2023-06-02 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et un agent de charge organique |
| FR3149208B1 (fr) | 2023-06-02 | 2026-03-20 | Oreal | Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane |
| FR3149203B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| WO2025002339A1 (zh) * | 2023-06-30 | 2025-01-02 | 上海赛增医疗科技有限公司 | 新型工程裂解酶及其用途 |
| FR3152394B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe |
| FR3152396A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane |
| FR3152393B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale |
| WO2025093666A1 (en) | 2023-11-01 | 2025-05-08 | University Of Copenhagen | Treatment of lymphoma |
| CN118045161B (zh) * | 2024-02-20 | 2024-08-27 | 通化康元生物科技有限公司 | 林蛙抗菌肽浓缩液在制备抗支原体的药物中的应用 |
| CN118240803B (zh) * | 2024-05-23 | 2024-08-13 | 中国农业科学院生物技术研究所 | 牛瘤胃来源的溶菌酶及其应用 |
| WO2026052743A1 (en) | 2024-09-04 | 2026-03-12 | Micreos Human Health B.V. | Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties |
| CN119431510B (zh) * | 2024-11-26 | 2025-11-14 | 中国人民解放军陆军军医大学 | 一种抗鲍曼不动杆菌的抗菌肽及其制备方法和应用 |
| CN119798365B (zh) * | 2025-01-06 | 2025-11-21 | 西北农林科技大学 | 一种寡肽及其在改性溶菌酶增强抑菌谱和抑菌活性中的应用 |
| CN120678882B (zh) * | 2025-06-30 | 2025-12-26 | 上海市农业科学院 | 猴头菇降血糖肽在制备抑制α-淀粉酶和α-葡萄糖苷酶活性药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989000194A1 (en) * | 1987-07-06 | 1989-01-12 | Louisiana State University Agricultural And Mechan | Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides |
| GB8816693D0 (en) | 1988-07-13 | 1988-08-17 | Agricultural & Food Res | Viral enzyme & gene |
| US7572602B1 (en) * | 2004-12-03 | 2009-08-11 | The United States Of America As Represented By The Secretary Of Agriculture | Nucleic acid encoding endolysin fusion protein |
| DE102005040347A1 (de) * | 2005-08-25 | 2007-03-01 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien |
| CA2736062A1 (en) * | 2008-07-24 | 2010-01-28 | The United State Of America, As Represented By The Secretary Of Agricuure | Triple acting antimicrobials that are refractory to resistance development |
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| US8383102B2 (en) * | 2009-05-21 | 2013-02-26 | The United States Of America As Represented By The Secretary Of Agriculture | Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens |
| DK2445515T3 (en) * | 2009-06-26 | 2016-07-04 | Univ Leuven Kath | antimicrobial agents |
| KR101701890B1 (ko) * | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
| SG178440A1 (en) * | 2009-08-24 | 2012-04-27 | Univ Leuven Kath | New endolysin obpgplys |
| EA037276B1 (ru) * | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
-
2010
- 2010-12-23 EP EP10196890A patent/EP2468856A1/en not_active Withdrawn
-
2011
- 2011-12-22 AR ARP110104879A patent/AR084536A1/es unknown
- 2011-12-23 JP JP2013545423A patent/JP2014507933A/ja active Pending
- 2011-12-23 WO PCT/EP2011/073908 patent/WO2012085259A2/en not_active Ceased
- 2011-12-23 CN CN201180068723XA patent/CN103403153A/zh active Pending
- 2011-12-23 CA CA2822732A patent/CA2822732C/en active Active
- 2011-12-23 EA EA201370145A patent/EA201370145A1/ru unknown
- 2011-12-23 EP EP11807927.6A patent/EP2655610B1/en not_active Not-in-force
- 2011-12-23 TW TW100148225A patent/TW201239095A/zh unknown
- 2011-12-23 US US13/997,058 patent/US20130344055A1/en not_active Abandoned
- 2011-12-23 AU AU2011347152A patent/AU2011347152B2/en not_active Ceased
- 2011-12-23 MX MX2013007313A patent/MX344257B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2822732C (en) | 2021-01-26 |
| EA201370145A1 (ru) | 2013-11-29 |
| CN103403153A (zh) | 2013-11-20 |
| WO2012085259A3 (en) | 2012-08-30 |
| AU2011347152B2 (en) | 2016-08-04 |
| EP2655610A2 (en) | 2013-10-30 |
| US20130344055A1 (en) | 2013-12-26 |
| TW201239095A (en) | 2012-10-01 |
| WO2012085259A2 (en) | 2012-06-28 |
| CA2822732A1 (en) | 2012-06-28 |
| MX2013007313A (es) | 2013-10-25 |
| AU2011347152A1 (en) | 2013-07-11 |
| JP2014507933A (ja) | 2014-04-03 |
| AR084536A1 (es) | 2013-05-22 |
| EP2468856A1 (en) | 2012-06-27 |
| EP2655610B1 (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX344257B (es) | Agentes antimicrobianos. | |
| MX2011013453A (es) | Agentes antimicrobianos. | |
| MX2011013288A (es) | Agentes antimicrobianos. | |
| WO2010023207A3 (en) | Antimicrobial agents | |
| GB201018518D0 (en) | Novel endolysin | |
| MX2012012345A (es) | Metodo de reduccion de biopeliculas. | |
| EA201270322A1 (ru) | НОВЫЙ ЭНДОЛИЗИН OBPgpLYS | |
| JP2014500714A5 (es) | ||
| BR112014027629A2 (pt) | misturas de polipeptídeo com atividade antibacteriana | |
| JP2012530510A5 (es) | ||
| AU2011206532A8 (en) | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) | |
| NZ701651A (en) | A bacteriophage for biocontrol of salmonella and in the manufacturing or processing of foods | |
| WO2015112980A3 (en) | Dermaseptin-type and piscidin-type antimicrobial peptides | |
| Heinzinger et al. | Evaluating the translational potential of bacteriocins as an alternative treatment for Staphylococcus aureus infections in animals and humans | |
| EA201991233A1 (ru) | Новый эндолизин | |
| Contreras et al. | Prevalence of methicillin-resistant Staphylococcus aureus in raw hamburgers and ready-to-eat sandwiches commercialized in supermarkets and fast food outlets in Brazil | |
| Bonhi et al. | Role of bacteriocin in tackling the global problem of multi-drug resistance: an updated review | |
| Sabur et al. | The unique capability of endolysin to tackle antibiotic resistance: cracking the barrier | |
| Wang et al. | Opportunities for nanomedicine in Clostridioides difficile infection | |
| Abbas et al. | Public health threats posed by biofilms and innovative strategies for their control | |
| Zameer et al. | Evaluation of antibiotic susceptibility in mixed culture biofilms | |
| Kumar et al. | Antimicrobial peptide resistance in Salmonella AMR: the role of surface binding and lipopolysaccharide remodelling: one health implications | |
| Vučemilović-Alagić | Antimicrobial activity of modified cell penetrating peptide and modified natural antimicrobial peptide against opportunistic (multiresistant) pathogens in hospital environment | |
| Bakar et al. | Microbiota, Biofilm, and Chronic Rhinosinusitis: A Transitory General Idea of Writings | |
| TH120358A (th) | สารต้านจุลินทรีย์ (antimicrobial aggents) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |